Entries by avantexb
Roche Acquires Ignyta for US$1.7 Billion at US$27.00 Per Share
SAN DIEGO – (BUSINESS WIRE) – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 […]
Market Research: Global Lung Cancer Therapeutics Market to contribute around $11.19 billion during the period 2017-2020
ResearchMoz presents professional and in-depth study of “Global Lung Cancer Therapeutics Market 2016-2020”. Published June 13, 2017 Medgadget, LLC. 2004-2016. All rights reserved. The Medical Revolution Will Be Blogged ResearchMoz presents professional and in-depth study of “Global Lung Cancer Therapeutics Market 2016-2020”. Lung cancer is a common cause of mortality and morbidity in both developed […]
World Lung Cancer Therapeutics Market – Opportunities and Forecasts, 2014 – 2022
World Lung Cancer Therapeutics Market Opportunities and Forecasts 2014-2017 & 2022: Leading Companies are Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Co, Pfizer, and Agennix – Research and Markets Published by Research and Markets Research and Markets has announced the addition of the “World Lung Cancer Therapeutics Market – Opportunities and Forecasts, 2014 – 2022” report […]
AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion
Fortune | Finance | Dan Primack Published April 28, 2016 Pharma giant AbbVie Inc. this morning said it will acquire privately held cancer drug developer Stemcentrx in a blockbuster deal that could be worth up to $10.2 billion. Not only would that make this one of the largest biotech acquisitions in recent memory, but also […]
Attacking The Big C: Funding To Cancer Therapeutics Jumps To $2.8B In 2015
Equity funding to private cancer therapeutics companies was up 153% in the year. The current quarter has already set a deal record. Published 2017 CB Insights Blog We recently highlighted how cancer drugs were an area of high interest for pharmaceutical corporates, with one fifth of their deals to private companies since 2013 going to cancer drugs and […]